BARDA Broad Agency Announcement (BAA)

We partner with companies and teams offering solutions to a broad range of national health security threats.

BAA Partnering Dashboard

29
BAA Submissions

82
COVID-19 Partnerships

29
Products Supported

magnifying glass

Seeking Partners To Fight Covid-19

BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003)

Diagnostic assays

Diagnostic bottle

Diagnostic assays

Advanced manufacturing technologies

vacines bottle

Advanced manufacturing technologies

Screening Tests at Point of Care

vacines bottle

Screening Tests at Point of Care

ABOUT BARDA BROAD AGENCY ANNOUNCEMENTS

BARDA supports advanced research and development of medical countermeasures and is a component of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).

Stages of Funding Support

White Paper Submission and Review
Full proposal Submission and BARDA Review
Negotiation
Award
Milestone Based Follow-On Funding Decision

OPPORTUNITIES TO PARTNER WITH BARDA

  • AOI 7.7.1 Diagnostic Assay for Human Coronaviruses
  • AOI 7.7.2 Diagnostic Assay for Detection of SARS-CoV-2 Virus
  • AOI 7.7.3 Diagnostic Assay for Detection of COVID-19 Neutralizing Antibodies
  • AOI 7.7.5 Screening Tests at Point of Care (2-minute Time to Result)
  • AOI 17 Advanced Manufacturing Technologies
Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov